Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arena Must Deal With Rat Neoplasms To Move Forward With Lorqess

Executive Summary

A major task confronting Arena as it pursues approval of Lorqess is to provide FDA with an explanation that shows the neoplasms found in rats during animal studies of the obesity drug are not a predictor of cancer risk in humans.

Related Content

The Omniscient Regulator: QRxPharma’s Unusual Take on FDA and Investor Calls
Arena Finds Antidote For Belviq’s Theoretical Risk Of Valvulopathy In Mechanistic Studies
Lorcaserin Makes It Past Panel On The Strength Of Effect In Some Patients
Lorcaserin Safety Questions Can Be Answered In Post-Market Study, Panel Tells FDA
Lorcaserin Advisory Committee Will Again Be Weighed Down By Safety Concerns
Lorcaserin Re-Review Expected To Address Risk/Benefit Trade-offs, Rat Tumors
Arena Ready For FDA To Reconsider Weight-Loss Drug Lorcaserin
FDA Issues Complete Response Letter for Arena's Lorcaserin
Positive Two-Year Data Boost Prospects For Vivus' Qnexa
Positive Two-Year Data Boost Prospects For Vivus' Qnexa





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts